<DOC>
	<DOCNO>NCT00390416</DOCNO>
	<brief_summary>This study do find effect drug named/called bevacizumab patient patient ' tumor give together standard chemotherapy drug . Making new blood vessel seem important many tumor grow . Bevacizumab new type treatment cancer block growth new tumor blood vessel . In study , researcher combine bevacizumab chemotherapy drug standard patient 's disease include cisplatin , docetaxel , fluorouracil , leucovorin . The way original combination cisplatin , docetaxel , fluorouracil give cause many side effect include gastrointestinal symptom , weakness , drop blood count infection fight cell . For study , researcher modify combination give low dos medicine often , reduce side effect chemotherapy . Patients receive bevacizumab modify combination docetaxel , cisplatin , fluorouracil . This study call phase II study . In study , everyone similar tumor receive treatment .</brief_summary>
	<brief_title>Study Docetaxel , Cisplatin , Fluorouracil ( Modified DCF ) With Bevacizumab Patients With Unresectable Metastatic Gastroesophageal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients must histologically cytologically confirm metastatic unresectable gastric esophageal adenocarcinoma , include GEJ adenocarcinoma classify accord Siewert 's classification type I , II , III . Histological documentation local recurrence metastasis strongly encourage , unless risk procedure outweigh potential benefit confirm metastatic disease . If histologic confirmation , metastases recurrence require documentation 2nd radiographic procedure ( i.e . positron emission tomography [ PET ] scan magnetic resonance image [ MRI ] addition compute tomography [ CT ] scan ) . If imaging procedure confirm recurrent metastatic disease , biopsy confirmation require . Patients must disease evaluate radiographically . This may measurable disease nonmeasurable disease . Measurable disease define measure least one dimension &gt; = 20 mm conventional technique , &gt; = 10 mm high resolution image . Disease identify radiology study , meet criterion measurable disease , consider nonmeasurable see section 12.1.1 protocol detail . No prior chemotherapy metastatic unresectable disease . Patients may receive prior adjuvant therapy ( chemotherapy and/or chemoradiation ) 6 month elapse end adjuvant therapy registration . Patients may receive prior docetaxel cisplatin , bevacizumab novel biologic antiangiogenic agent . Age 18 year old . Karnofsky performance status &gt; = 70 % ( ECOG performance status 01 ) . Peripheral neuropathy &lt; = grade 1 Hematologic ( minimal value ) : White blood cell count &gt; = 3000/mm3 Absolute neutrophil count &gt; = 1500 cells/mm3 Hemoglobin &gt; = 9.0 g/dl Platelet count &gt; = 100,000/mm3 Hepatic ( minimal value ) : Total bilirubin &lt; = upper limit normal ( ULN ) AST ALT alkaline phosphatase must within eligible range . In determine eligibility , abnormal two value ( AST ALT ) use . AST ALT alkaline phosphatase 11.5 time upper limit normal . Kidney function ( minimal value ) : Serum creatinine &lt; = 1.5 mg/dl Urinalysis &lt; 2+ proteinuria ; urine protein ( mg/dl ) /urine creatinine ( mg/dl ) ratio ( Up/c ) &lt; 1.0 The patient PT ( INR ) &lt; = 1.5 PTT &lt; = 3 second upper limit normal patient anticoagulation therapy . If patient fulldose anticoagulant , follow criterion meet enrollment : 1 . The patient must inrange INR ( usually 2 3 ) stable dose warfarin stable dose LMW heparin . 2 . The patient must active bleed pathological condition carry high risk bleeding ( e.g . tumor involve major vessel , know varix ) . Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . Ability understand inform consent sign write informed consent document prior initiation protocol therapy . Patients receive previous chemotherapy treatment metastatic unresectable gastric , GEJ , esophageal adenocarcinoma ineligible . Patients receive previous pre postoperative chemotherapy chemoradiation ineligible therapy complete less 6 month prior study registration . Patients must recover adverse event previous therapy . Patients receive previous bevacizumab , docetaxel , cisplatin . Patients history another neoplastic disease within past three year , exclude basal cell carcinoma skin , cervical carcinoma situ , nonmetastatic prostate cancer . Patients brain central nervous system metastasis , include leptomeningeal disease . Minor surgical procedure fine needle aspiration , core biopsy , laparoscopy , mediport placement within 7 day prior initiate treatment . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 0 Anticipation need major surgical procedure course study . Pregnant ( positive pregnancy test ) breast feeding . Urine protein : creatinine ( Up/c ) ratio &gt; = 1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior initiation treatment . Serious , nonhealing wound , ulcer , bone fracture . Blood pressure &gt; 150/100 mmHg Significant cardiac disease define : Unstable angina New York Heart Association ( NYHA ) grade II great Congestive heart failure History myocardial infarction within 6 month Evidence bleed diathesis coagulopathy . History stroke cerebrovascular accident ( CVA ) within 6 month . Clinically significant peripheral vascular disease . Clinically significant hearing loss ring ear . Patients history severe hypersensitivity reaction TaxotereÂ® drug formulate polysorbate 80 . Inability comply study and/or followup procedure . Patients medical condition reason , investigator 's opinion , make patient unstable participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Gastroesophageal</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Fluorouracil</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Metastatic Gastroesophageal Adenocarcinoma</keyword>
	<keyword>06-096</keyword>
</DOC>